Furthermore, either pharmacological (the GSK2606414 PERK inhibitor) or genetic inhibition of the PERK pathway was beneficial in these experimental models of PD (Celardo et al., 2016). This evidence concerns the gene EIF2AK3 and Parkinson disease.